Articles published by Candel Therapeutics
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
November 14, 2024
From Candel Therapeutics
Via GlobeNewswire
Tickers
CADL
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From Candel Therapeutics
Via GlobeNewswire
Tickers
CADL
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
August 13, 2024
From Candel Therapeutics
Via GlobeNewswire
Tickers
CADL
Candel Therapeutics to Join Russell 3000® Index
June 11, 2024
From Candel Therapeutics
Via GlobeNewswire
Tickers
CADL
FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
May 30, 2024
From Candel Therapeutics
Via GlobeNewswire
Tickers
CADL
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 14, 2024
From Candel Therapeutics
Via GlobeNewswire
Tickers
CADL
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
February 13, 2024
From Candel Therapeutics
Via GlobeNewswire
Tickers
CADL
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
December 12, 2023
From Candel Therapeutics
Via GlobeNewswire
Tickers
CADL
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
November 09, 2023
From Candel Therapeutics
Via GlobeNewswire
Tickers
CADL
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
November 04, 2023
From Candel Therapeutics
Via GlobeNewswire
Tickers
CADL
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.